December 26, 2025 A newly released clinical review is drawing attention within medical and regulatory communities by consolidating available evidence on the side-effect profile of a widely prescribed ...

Health system C-suites are approaching a pivotal inflection point. By 2030, leaders will be navigating an environment defined by persistent margin pressure, workforce scarcity, accelerating digital ...

As part of conversations between AI healthcare leaders on the podcast AI Amplified this year, a clear picture emerged of where artificial intelligence is genuinely transforming healthcare — and where ...

The adoption of the FAIR model was pivotal in transforming our cybersecurity strategy into a measurable, business-aligned ...

As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.

Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...

Background The growing population of patients with adult congenital heart disease (ACHD) present complex lifelong care needs ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the ...

By 2026, many exam rooms will have an AI listener that will take notes on the entire conversation and provide structured data ...

A parliamentary panel urged India to create a single, independent Ayush drug regulator. It called for unified standards, better ADR reporting, and a digital CTMS to ensure safety and global trust.

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety artefacts, evidence repeatability and lifecycle controls. CITY OF LONDON, GB / ACCESS ...

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety artefacts, evidence repeatability and lifecycle controls. CITY OF LONDON, GB / ACCESS N ...